loading page

Allergic bronchopulmonary aspergillosis in children
  • +5
  • Sara Manti,
  • Giuseppe Fabio Parisi,
  • Maria Papale,
  • Amelia Licari,
  • Elena Chiappini,
  • Enza Mulè,
  • Novella Rotolo,
  • salvatore leonardi
Sara Manti
UOC Genetics and Immunology Paediatrics
Author Profile
Giuseppe Fabio Parisi
University of Catania
Author Profile
Maria Papale
University of Catania School of Medicine
Author Profile
Amelia Licari
Fondazione IRCCS Policlinico San Matteo
Author Profile
Elena Chiappini
University of Florence, Meyer Children's Hospital
Author Profile
Enza Mulè
University of Catania School of Medicine
Author Profile
Novella Rotolo
University
Author Profile
salvatore leonardi
University of Catania School of Medicine
Author Profile

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disease caused by Aspergillus induced hypersensitivity that occurs in immunocompetent but susceptible patients with asthma and/or cystic fibrosis (CF). In children, ABPA remains mostly undiagnosed, resulting in one of the most common causes of poorly controlled asthma and highly significant morbidity in children with CF. Currently, no specific diagnostic criteria of ABPA for children are available. Corticosteroids and itraconazole are the mainstays of therapy, althoughthere is a lack of randomized clinical trials regarding their usefulness for ABPA in children. Several monoclonal antibodies, such asomalizumab and mepolizumab, may be potential therapies for refractory ABPA in pediatric patients; however, further data are required to clarify the optimal dose and duration of therapy as a routine treatment approach.

Peer review status:ACCEPTED

07 Aug 2020Submitted to Pediatric Allergy and Immunology
12 Aug 2020Editorial Decision: Accept